Medical specialists from Canada tagged as investigators in clinical trials studying Leukemia, Myeloid, Chronic-Phase

Total 10 results

Ashley Chopek
Seen in:
- Manitoba, Winnipeg, CancerCare Manitoba
Trials:
- NCT04759586 (Principal Investigator)
- NCT05457556 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT03223753 (Principal Investigator)
Conditions:
Bruno Michon
Seen in:
- Quebec, CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
- Quebec, Centre Hospitalier Universitaire de Quebec
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT04166409 (Principal Investigator)
- NCT01790152 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
Conditions:
Craig Erker
Seen in:
- Nova Scotia, Halifax, IWK Health Centre
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT02724579 (Principal Investigator)
- NCT03871257 (Principal Investigator)
- NCT04166409 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT03126916 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT00898365 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT05602194 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT04089358 (Principal Investigator)
Conditions:
Donna L. Johnston
Seen in:
- Ontario, Ottawa, Children's Hospital of Eastern Ontario
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT02724579 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT03126916 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT00898365 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT00772200 (Principal Investigator)
- NCT03223753 (Principal Investigator)
- NCT00082745 (Principal Investigator)
Conditions:
Monia Marzouki
Seen in:
- Quebec, Montreal, Centre Hospitalier Universitaire Sainte-Justine
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT03155620 (Principal Investigator)
- NCT02724579 (Principal Investigator)
- NCT05071209 (Principal Investigator)
- NCT03871257 (Principal Investigator)
- NCT05286801 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05359237 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT05828069 (Principal Investigator)
Conditions:
Oussama A. Abla
Seen in:
- Ontario, Toronto, Hospital for Sick Children
Trials:
- NCT03817398 (Principal Investigator)
- NCT05828069 (Principal Investigator)
Conditions:
Sarah J. McKillop
Seen in:
- Alberta, Edmonton, University Of Alberta Hospital
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT00898365 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT04089358 (Principal Investigator)
- NCT00082745 (Principal Investigator)
Conditions:
Shayna M. Zelcer
Seen in:
- Ontario, London, Children's Hospital
Trials:
- NCT04759586 (Principal Investigator)
- NCT02724579 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT03126916 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT00082745 (Principal Investigator)
Conditions:
Stephanie Mourad
Seen in:
- Quebec, Montreal, The Montreal Children's Hospital of the MUHC
Trials:
- NCT04759586 (Principal Investigator)
- NCT03871257 (Principal Investigator)
- NCT04166409 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT04994132 (Principal Investigator)
Conditions:
Uma H. Athale
Seen in:
- Ontario, Hamilton, McMaster Children's Hospital at Hamilton Health Sciences
Trials:
- NCT04759586 (Principal Investigator)
- NCT02724579 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT03126916 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT00772200 (Principal Investigator)
- NCT00082745 (Principal Investigator)
Conditions:

Clinical Trials on Leukemia, Myeloid, Chronic-Phase

Asan Medical Center

Terminated

Chronic Myelod Leukemia Registry at Asan Medical Center

Leukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated Phase

Korea, Republic of
ChemGenex Pharmaceuticals

Terminated

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Myeloid Leukemia, Chronic, Chronic-Phase | Myeloid Leukemia, Chronic | Myeloid Leukemia, Chronic, Accelerated-Phase | Blast Phase

United States
Newcastle University
Bristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaborators

Completed

Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia (SPIRIT2)

Myeloid Leukemia, Chronic, Chronic Phase

United Kingdom
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Chronic Myelogenous Leukemia - Chronic Phase

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

CML, Chronic Phase | CML, Accelerated Phase

China
Fundacion Espanola para la Curacion de la Leucemia...
Pfizer; Roche Farma, S.A

Terminated

Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients

Chronic Phase-Chronic Myeloid Leukemia

Spain
Takeda

Active, not recruiting

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses (OPTIC)

Myeloid Leukemia, Chronic, Chronic Phase

United States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
Korean Society of Hematology

Not yet recruiting

A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia (AsterA)

Chronic Myeloid Leukemia, Chronic Phase
National Cancer Institute (NCI)

Terminated

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation; H. Jean Khoury Cure CML Consortium

Recruiting

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

Chronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid Leukemia

United States

Medical specialists from Canada tagged as investigators in clinical trials studying Leukemia, Myeloid, Chronic-Phase

Clinical Trials on Leukemia, Myeloid, Chronic-Phase

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations